Literature DB >> 30542708

Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma.

Yanqing Zhang1, Jiaqi Pan1, Desheng Xu2, Zhengkai Yang3, Jingxue Sun4, Lulu Sun4, Yanmeizhi Wu4, Hong Qiao4.   

Abstract

Circulating microRNAs (miRNAs) are promising diagnostic markers in various types of cancers, including papillary thyroid carcinoma (PTC). However, there is sparse information reported with regards to miRNA expression in papillary thyroid microcarcinoma (PTMC) or concerning the role of a combination of miRNAs and ultrasound (US) in the diagnosis of PTMC before surgery. Therefore, we designed a study that aimed to evaluate miRNA expression levels and their potential associations with US findings and determine whether miRNAs could be used as diagnostic and prognostic biomarkers of PTMC. miR‑222, miR‑221, miR‑146b and miR‑21 levels were determined using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) in serum from 58 patients with PTMC and 47 with PTC, 35 patients with benign thyroid nodules (BTN) and 40 control subjects. Expression levels of the four miRNAs in serum were evaluated before and after surgery. The results indicated that miR‑222, miR‑221, miR‑146b and miR‑21 expression levels were higher in the PTMC samples than in those from the BTN and control groups and the combination of miRNAs and US had a high sensitivity and specificity for discrimination between BTN and PTMC by receiver operating characteristic (ROC) curve analysis and improved the accuracy of diagnosis of PTMC before surgery. In addition, serum miRNA expression levels were significantly related to poor prognostic factors including metastatic lymph nodules (MLNs), multifocal and bilateral lesions, advanced stage and high‑risk PTMC patients. The miRNA expression levels in serum from PTMC patients were rapidly reduced after surgery compared with levels before surgery. In addition, we also analyzed the miRNA expression levels in serum from patients who were divided into two groups according to factors indicating a good or poor prognosis associated with PTMC after surgery. The results suggested that after surgery, the miR‑222, miR‑146b and miR‑21 expression levels were significantly higher in the poor prognosis group compared with these levels in the good prognosis group. Serum miRNA expression levels helped distinguish between benign and malignant nodules and were associated with a poor prognosis in PTMC. Circulating miRNAs may be useful as follow‑up biomarkers and as diagnostic and prognostic tools.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30542708     DOI: 10.3892/or.2018.6776

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

Review 1.  Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.

Authors:  Georgios Geropoulos; Kyriakos Psarras; Maria Papaioannou; Dimitrios Giannis; Maria Meitanidou; Konstantinos Kapriniotis; Nikolaos Symeonidis; Efstathios T Pavlidis; Theodoros E Pavlidis; Konstantinos Sapalidis; Nada Mabrouk Ahmed; Tarek Ezzat Abdel-Aziz; Mohammad M R Eddama
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.

Authors:  Xiao-Jiao Li; Rong Wen; Dong-Yue Wen; Peng Lin; Deng-Hua Pan; Li-Jie Zhang; Yu He; Lin Shi; Yong-Ying Qin; Yun-Hui Lai; Jing-Ni Lai; Jun-Lin Yang; Qin-Qiao Lai; Jun Wang; Jun Ma; Hong Yang; Yu-Yan Pang
Journal:  Mol Med Rep       Date:  2020-07-08       Impact factor: 2.952

Review 3.  Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies.

Authors:  Barbara Pardini; Alexandru Anton Sabo; Giovanni Birolo; George Adrian Calin
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

Review 4.  MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Authors:  Maria Papaioannou; Angeliki G Chorti; Anthoula Chatzikyriakidou; Kleanthis Giannoulis; Sohail Bakkar; Theodosios S Papavramidis
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

5.  Biomarker Value of miR-221 and miR-222 as Potential Substrates in the Differential Diagnosis of Papillary Thyroid Cancer Based on Data Synthesis and Bioinformatics Approach.

Authors:  Shang Cai; Jiayan Ma; Yong Wang; Yuxing Cai; Liwei Xie; Xiangying Chen; Yingying Yang; Qiliang Peng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-07       Impact factor: 5.555

6.  Diagnostic Significance of FNAB miRNA Expression in Papillary Thyroid Carcinoma.

Authors:  Romena Laukienė; Laima Ambrozaityte; Loreta Cimbalistienė; Algirdas Utkus; Algirdas Edvardas Tamosiunas
Journal:  Diagnostics (Basel)       Date:  2022-06-03

7.  Ultrasound Radiomics Nomogram to Diagnose Sub-Centimeter Thyroid Nodules Based on ACR TI-RADS.

Authors:  Wenwu Lu; Di Zhang; Yuzhi Zhang; Xiaoqin Qian; Cheng Qian; Yan Wei; Zicong Xia; Wenbo Ding; Xuejun Ni
Journal:  Cancers (Basel)       Date:  2022-10-03       Impact factor: 6.575

8.  Papillary Thyroid Carcinoma Tissue miR-146b, -21, -221, -222, -181b Expression in Relation with Clinicopathological Features.

Authors:  Aistė Kondrotienė; Albertas Daukša; Daina Pamedytytė; Mintautė Kazokaitė; Aurelija Žvirblienė; Dalia Daukšienė; Vaida Simanavičienė; Raimonda Klimaitė; Ieva Golubickaitė; Rytis Stakaitis; Valdas Šarauskas; Rasa Verkauskienė; Birutė Žilaitienė
Journal:  Diagnostics (Basel)       Date:  2021-03-02

9.  Radiomics Nomogram for Identifying Sub-1 cm Benign and Malignant Thyroid Lesions.

Authors:  Xinxin Wu; Jingjing Li; Yakui Mou; Yao Yao; Jingjing Cui; Ning Mao; Xicheng Song
Journal:  Front Oncol       Date:  2021-06-07       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.